$5.56
▼ $-0.02
(-0.36%)
Vol 812K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.2B
ROE
-86.6%
Margin
-4253.9%
D/E
31.55
Beta
0.33
52W
$2–$7
Wall Street Consensus
14 analysts · Apr 20265
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
92.9%
Buy Rating
Price Chart
Similar Stocks
ZBIO
Zenas Biopharma Inc
$2.3B
TSHA
Taysha Gene Therapies Inc
$1.5B
NVAX
Novavax Inc
P/E 3.2
$1.1B
CRVS
Corvus Pharmaceuticals Inc
$575.1M
AVBP
ArriVent BioPharma Inc
$830.6M
GERN
Geron Corp
$842.6M
KALV
Kalvista Pharmaceuticals Inc
$816.3M
CTMX
CytomX Therapeutics Inc
P/E 25.8
$721.8M
CMPX
Compass Therapeutics Inc.
$955.1M
Earnings
Beat rate: 25.0%
Next Report
May 11, 2026
EPS Estimate: $-0.14
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.14 | — | — |
| Dec 2025 | $-0.12 | $-0.13 | $-0.01 |
| Sep 2025 | $-0.14 | $-0.14 | $0.00 |
| Jun 2025 | $-0.12 | $-0.14 | $-0.02 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -69.0% | -69.0% | -69.0% | -69.0% | -86.6% | -86.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -4253.9% | -4253.9% | -4253.9% | -4253.9% | -4253.9% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 24.61 | 24.61 | 24.61 | 24.61 | 31.55 | 31.55 |
| Current Ratio | 11.08 | 11.08 | 11.08 | 11.08 | 7.65 | 7.65 |
Key Ratios
ROA (TTM)
-65.4%
P/S (TTM)
4718.89
P/B
3.1
EPS (TTM)
$-0.53
CF/Share
$-0.31
52W High
$7.01
52W Low
$1.89
$1.89
52-Week Range
$7.01
How does SVRA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
SVRA valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
4718.9
▲
36623%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
3.1
▲
25%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
SVRA profitability vs Biotechnology peers
ROE
-86.6%
▼
29%
below
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-4253.9%
▼
1383%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-65.4%
▼
40%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
SVRA financial health vs Biotechnology peers
D/E ratio
31.6
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
7.7
▲
72%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.3
▼
66%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
SVRA fundamentals radar
SVRA
Peer median
Industry
SVRA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio